ArticleCurrent opinion in chemical engineering2013
Back to the future: recombinant polyclonal antibody therapeutics.
Article in Current opinion in chemical engineering, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- Review
- Single-Batch Expression of an Experimental Recombinant Snakebite Antivenom Based on an Oligoclonal Mixture of Human Monoclonal Antibodies.Biotechnology journal · 2024Article
- Immune Checkpoint Glycoproteins Have Polymorphism: Are Monoclonal Antibodies Too Specific?Current oncology (Toronto, Ont.) · 2023Article
- Avidity in antibody effector functions and biotherapeutic drug design.Nature reviews. Drug discovery · 2022Review
- Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases.Human vaccines & immunotherapeutics · 2022Review
- Rapid-format recombinant antibody-based methods for the diagnosis ofFrontiers in microbiology · 2022Review
- Potential of Nanotechnology-based Formulations in Combating Pulmonary Infectious Diseases: A Current Scenario.Current pharmaceutical design · 2022Review
- A general strategy to control antibody specificity against targets showing molecular and biological similarity: Salmonella case study.Scientific reports · 2020Article
- Characterizing Epitope Binding Regions of Entire Antibody Panels by Combining Experimental and Computational Analysis of Antibody: Antigen Binding Competition.Molecules (Basel, Switzerland) · 2020Article
- Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives.International immunopharmacology · 2020Review
- Species-Specific Involvement of Integrin αIIbβ3 in a Monoclonal Antibody CH12 Triggers Off-Target Thrombocytopenia in Cynomolgus Monkeys.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- Engineering therapeutic antibodies to combat infectious diseases.Current opinion in chemical engineering · 2018Article
- Application of Antibody-Mediated Therapy for Treatment and Prevention ofFrontiers in microbiology · 2018Review
- Promises and pitfalls for recombinant oligoclonal antibodies-based therapeutics in cancer and infectious disease.Current opinion in immunology · 2016Review
- The Cloning and Expression of Human Monoclonal Antibodies: Implications for Allergen Immunotherapy.Current allergy and asthma reports · 2016Review
- Oligoclonal antibodies to target the ErbB family.Expert opinion on biological therapy · 2015Review
- Broadly neutralizing anti-influenza virus antibodies: enhancement of neutralizing potency in polyclonal mixtures and IgA backbones.Journal of virology · 2015Article
- A tripartite cocktail of chimeric monoclonal antibodies passively protects mice against ricin, staphylococcal enterotoxin B and Clostridium perfringens epsilon toxin.Toxicon : official journal of the International Society on Toxinology · 2014Article
- Technological advances in precision medicine and drug development.Expert review of precision medicine and drug developmentArticle
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Antibody therapeutics are one of the fastest growing classes of pharmaceuticals, with an annual US market over $20 billion, developed to treat a variety of diseases including cancer, auto-immune and infectious diseases. Most are currently administered as a single molecule to treat a single disease, however there is mounting evidence that cocktails of multiple antibodies, each with a unique binding specificity and protective mechanism, may improve clinical efficacy. Here, we review progress in the development of oligoclonal combinations of antibodies to treat disease, focusing on identification of synergistic antibodies. We then discuss the application of modern antibody engineering technologies to produce highly potent antibody preparations, including oligoclonal antibody cocktails and truly recombinant polyclonal antibodies. Specific examples illustrating the synergy conferred by multiple antibodies will be provided for diseases caused by botulinum toxin, cancer and immune thrombocytopenia. The bioprocessing and regulatory options for these preparations will be discussed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.